Developing innovative cancer treatments tackling GPCR mediated-immunosuppression
| Discovery | Candidate | Preclinical | Clinical | Partner | |
|---|---|---|---|---|---|
| A2aR/A2bR antagonist + |
Preclinical
|
||||
| EP4R antagonist (DT-9081) + | Preclinical | ||||
| Anti-CCR8 antibody + | Discovery | ||||
| Undisclosed GPCR targets + | Discovery | ||||
We build a high value pipeline focused on GPCRs to rearm immune system against tumors.
![](https://www.domaintherapeutics.com/wp-content/uploads/2020/03/merck-1-e1637145445707.png")
A2aR/A2bR antagonist
![](https://www.domaintherapeutics.com/wp-content/uploads/2021/09/Logo-DT-EN-White.svg"){kind=logo}
EP4R antagonist (DT-9081)
Anti-CCR8 antibody
Undisclosed GPCR targets
We are advancing multiple first-in-class and best-in class programs to tackle GPCR-mediated immunosuppression in immune-oncology.
